Managing Re-Consent in Long-Term Extension Clinical Trials

As clinical research progresses beyond the primary endpoint, many trials transition into long-term extension (LTE) phases. These studies allow continued access to investigational therapies and further evaluation of long-term safety and efficacy. However, transitioning participants into LTE studies requires fresh ethical oversight — specifically, a formal re-consent process. This tutorial outlines best practices for obtaining re-consent in LTE trials, aligning with GCP, GMP documentation, and regulatory expectations.

What Are Long-Term Extension Studies?

LTE studies are follow-up clinical trials offered to participants who completed a parent study. Objectives may include:

• Monitoring long-term safety and adverse events
• Evaluating durability of efficacy
• Allowing continued therapeutic benefit post primary trial

Why Re-Consent Is Required for LTE Studies:

• The LTE phase often involves new endpoints, risks, or procedures
• Regulatory bodies such as USFDA and EMA mandate a separate informed consent for LTE participation
• Participant autonomy must be preserved; continued participation cannot be assumed
• Study protocol and Investigational Product (IP) characteristics may have evolved

Timing and Process of Re-Consent in LTE Trials:

Step 1: Draft a New Informed Consent Form (ICF)

• Clearly distinguish LTE objectives from the main study
• Include risks associated with prolonged drug exposure
• Mention new procedures or assessments, if any
• Describe duration and participant responsibilities

Step 2: Obtain Ethics Committee/IRB Approval

• Submit LTE protocol and new ICF for ethical review
• Include any updates to the Investigator’s Brochure
• Provide justifications for participant eligibility in LTE

Step 3: Train Investigators and Site Personnel

Staff must be trained on the differences between the main and extension studies. Use SOPs available at Pharma SOP templates to ensure consistency.

Step 4: Conduct Participant Re-Consent

• Offer re-consent before the first LTE visit
• Explain new objectives, risks, and timelines
• Allow time for questions and voluntary decision-making
• Document signed ICF and discussion in source notes

Elements to Include in the LTE Informed Consent Form:

• Statement clarifying LTE as a new study phase
• New data handling and reporting obligations
• Modified withdrawal criteria or safety monitoring plans
• Contact details for queries or complaints
• Updated compensation clauses (if applicable)

Participant Communication Strategies:

• Use layperson language to explain LTE differences
• Highlight changes in benefit-risk ratio
• Assure participants that refusal to participate will not impact routine care
• Use visuals and infographics for better understanding

Documentation and Record Keeping:

• File the signed LTE ICF in participant records
• Log consent in the site’s informed consent tracker
• Retain old ICFs for audit trail and regulatory inspection
• Ensure version control and track updates systematically

Audit and Regulatory Expectations:

Best Practices for Re-Consent in LTE Trials:

1. Start early — initiate LTE discussion during final visits of the main study
2. Prepare a participant handout outlining LTE rationale
3. Ensure ICF readability and comprehension assessments
4. Use AV recording for re-consent in countries like India, as per CDSCO
5. Engage LARs or caregivers when applicable

Challenges and Mitigation:

• Challenge: Participant fatigue or reluctance
• Mitigation: Emphasize continued health monitoring and access to investigational treatment
• Challenge: Delayed EC/IRB approvals
• Mitigation: Submit LTE protocols in parallel with main study closure reports
• Challenge: Multiple ICF versions
• Mitigation: Use version-controlled trackers and standardized forms

Real-World Example:

In a Phase III rheumatoid arthritis study, participants completing 48 weeks of the core study were offered entry into a 2-year LTE trial. New consent forms highlighted prolonged exposure risks, liver enzyme monitoring, and withdrawal flexibility. The IRB mandated re-consent using a clearly marked LTE ICF. As recommended on Stability Studies, detailed documentation was maintained, ensuring transparency and compliance.

Conclusion:

Re-consent in long-term extension studies is not merely an administrative requirement—it is a reaffirmation of the participant’s autonomy and the trial’s commitment to ethical conduct. A clear, timely, and well-documented re-consent process safeguards both participant rights and the integrity of clinical research. By integrating SOPs, staff training, and participant-centered communication, sponsors and sites can manage LTE transitions effectively and compliantly.